Verona Pharma has made significant progress over the last eighteen months reporting unequivocally positive results from all three parts of its Phase I/IIa trial of RPL554 in healthy subjects and COPD during 2015 and positive headline data from its dose ranging Phase IIa trial of RPL554 in asthma patients earlier this month. The compound continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment ....
